WittKieffer Impactful Leaders Podcast
What if medicine could move beyond managing decline to restoring human function? In this episode of Converge, Jerry McLaughlin, CEO of Life Biosciences, explores the emerging science of epigenetic reprogramming and its potential to transform how we treat age-related disease. Drawing on decades in biopharma, McLaughlin reflects on the shift from symptom management to targeting the root causes of aging at the cellular level. The conversation centers on a pivotal milestone: dosing the first human patient with an epigenetic restoration therapy designed to treat optic neuropathies, including glaucoma and NAION. McLaughlin shares how the field is evolving from hypothesis to clinical validation—and why rigor, evidence, and disciplined execution must replace hype. From commercialization strategy to scientific breakthroughs, this episode offers a rare, insider perspective on where longevity science intersects with patient impact—and what it will take to bring these therapies to scale.
97 episodes
Comments
0Be the first to comment
Sign up now and become a member of the WittKieffer Impactful Leaders Podcast community!